The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday. Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities and also for reducing pro-inflammatory cytokines, leading to faster recovery. A number of global studies have confirmed that cardiac complications during course of COVID-19 infections and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs, he said. "Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt Ltd Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of
from Latest News https://ift.tt/3zl6vTP
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd
Home
Business
Business News
Business Standard
Latest News
Regulatory nod given to conduct clinical trials of Colchicine: CSIR
Saturday, June 12, 2021
Related Posts:
Today's picks: NTPC to Larsen & Toubro, hot stocks to watch on FridayFor NTPC, Keep a stop at 95.5 and go short from Latest News https://i… Read More
Top stock picks by CapitalVia Global Research: Buy HDFC Bank, UPLTechnical Calls by Gaurav Garg, Head of Research at CapitalVia Global … Read More
After Jyotriaditya Scindia joins BJP, forgery case against him reopenedScindia's close aide Pankaj Chaturvedi alleged that it was political v… Read More
MARKET LIVE: SGX Nifty plunges 450 pts as coronavirus declared pandemicCatch all the live market updates here from Latest News https://ift.t… Read More
0 comments: